Cancer patients without health insurance have not derived the same benefits from the introduction of ICIs as patients with private insurance.

The FDA has published more than 200 complete response letters, sent as replies for applications submitted from 2020 to 2024.

The FDA approved Lynozyfic (linvoseltamab-gcpt) to treat adults with relapsed/refractory multiple myeloma who have received at least 4 prior lines of therapy.

Ashwin Kishtagari, MD, of Vanderbilt University Medical Center in Nashville, summarizes 7 studies presented at the EHA 2025 Congress.

The Trump administration's recent travel and visa restrictions are preventing medical residents from starting their jobs in the US.

The addition of metformin “was generally well tolerated but did not result in the targeted benefit of a 20% reduction in risk of death in an unselected population,” the researchers wrote.

Mass firings and grant terminations have disrupted research and other operations at the National Cancer Institute.

The composition of the gut microbiome appears to be associated with treatment response in patients with pancreatic cancer, research suggests.

Under the “One Big Beautiful Bill Act,” 10.9 million Americans would lose health insurance by 2034, according to estimates from the Congressional Budget Office.

Cancer Therapy Advisor, a trusted source of medical news and feature content for healthcare providers, offers clinicians insight into the latest research to inform clinical practice and improve ...

Olaparib demonstrated activity in a phase 2 trial of patients who had advanced biliary tract cancer with homologous recombination repair (HRR) mutations. Results from this trial were presented at the ...

Breast cancer patients may have inferior recurrence-free survival after neoadjuvant chemotherapy if they are overweight or obese at diagnosis.